Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 370

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 370
---
 into collaboration or other license agreements with respect to, new vaccine candidates programs to add to our clinical pipeline or obtain access to vaccine delivery or other technologies that we view as complementary to our business. For example, we entered into the Vaxart Agreement with Vaxart in November 2025. Such transactions or arrangements can be costly, complex and time-consuming to negotiate, document, implement and maintain. Any current or future transactions or arrangements, including the Vaxart Agreement, that we enter into may not be successful. Such transactions or arrangements may involve numerous risks and challenges, including but not limited to the following:

•integrating new vaccine candidates or technology into our business may require significant time, capital investment, and resources, and our efforts to achieve such integration may not be successful;

•new vaccine candidates or technology may require clinical and other development in compliance with strict regulatory standards before approval, and such development efforts may not be successful;

•we or our collaborators may not be successful in conducting or completing clinical and other development activities necessary to apply for regulatory approval required for commercialization;

•the results of clinical trials of new vaccine candidates or of preclinical studies and clinical trials of new vaccine candidates may not be sufficient to obtain regulatory approvals required for commercialization;

•our collaborators may delay, stop or provide insufficient funding or resources for clinical trials (whether as a result of a business decision or necessitated by financial difficulties of such collaborator) or may fail to perform other contractual obligations to us;

•we may be required to commit substantial additional resources to the development of additional vaccine candidates;

•even if a product is approved, it may not be commercially successful due to market competition, pricing pressures, or difficulties in commercial scaling and distribution;

•our failure to meet our obligations under collaboration or license agreements, such as payment of development, regulatory or commercial milestone payments or future royalties, could result in the termination of our rights;

•disputes may arise between us and our collaborators with respect to the ownership of intellectual property developed pursuant to our collaborations;

•our collaborators may infringe the intellectual property rights of third parties, exposing us to potential litigation and liability;

•third parties may challenge the validity, enforceability, or scope of patents claiming new vaccine candidates or technology, which may result in such patents being narrowed, invalidated or held unenforceable;

•the third-party licensor may fail to obtain or lose patent protection for new vaccine candidates or technology or issued patents claiming the vaccine candidates or technology may expire, which could impact our competitive position; or

•we